论文部分内容阅读
加拿大多伦多消息:由遗传工程制成的首批乙型肝炎疫苗(市售商品名称为Recombi-vax-HB)已经加拿大批准用于人体。加拿大出售新疫苗公司的医学研究主任Brian White-Guay医师在记者招待会上说:“许多临床研究已证明,新疫苗能诱发抗乙型肝炎病毒感染的抗体,达到保护作用,在接种三次常规剂量疫苗的健康成人中,90％以上的人抗体水平升高。”他说,新疫苗对10岁以下儿童,效果为100％;其保护作用在有被乙型肝炎病毒感染
TORONTO, CANADA: The first Hepatitis B vaccine (available under the trade name Recombi-vax-HB) made by genetic engineering has been approved for human use in Canada. Brian White-Guay, MD, director of medical research at Canada’s New Vaccine Company, told a press conference: “Many clinical studies have shown that the new vaccine can induce antibodies against hepatitis B virus to achieve a protective effect. After vaccination with three conventional doses More than 90% of human antibodies are elevated in healthy people with the vaccine. ”He said the new vaccine had an effect of 100% for children under 10 years of age, with protection from hepatitis B virus infection